title: Leupeptin as a tool for the detection of the sites of catabolism of rat high-density lipoprotein apolipoproteins A-I and E.
abstract: Leupeptin, an inhibitor of lysosomal cathepsin activity, was injected intravenously into male rats. Tissues obtained from leupeptin-treated animals showed a depressed cathepsin activity when compared with tissues from saline-treated control animals. Leupeptin treatment did not change the hepatic activities and subcellular distribution of marker enzymes for mitochondria, microsomes and plasma membranes. Hepatic lysosomal cathepsin activity was specifically inhibited, but the subcellular distribution of all lysosomal marker enzymes tested was changed, indicating the occurrence of enlarged lysosomes in the leupeptin-treated animals. No significant differences were observed in the serum concentrations of protein, cholesterol, cholesteryl esters, phospholipids and apolipoproteins A-I, A-IV and E between leupeptin-treated rats and control animals. When radioiodinated asialofetuin was injected intravenously, the radiolabel was retained for an extended period of time in the liver of leupeptin-treated animals, indicating diminished catabolism of this protein in the liver. When rat high-density lipoprotein, labelled specifically in the apolipoprotein A-I or E moiety was injected intravenously, only the kidneys and the liver showed a leupeptin-induced accumulation of radioactivity. These studies provide evidence for an important contribution of the kidneys and the liver to the in vivo catabolism of high-density lipoprotein apolipoproteins, using a method completely different from sugar-containing labelling compounds.
authors.forename: F M
authors.initials: FM
authors.lastname: van 't Hooft
authors.forename: G M
authors.initials: GM
authors.lastname: Dallinga-Thie
authors.forename: A
authors.initials: A
authors.lastname: van Tol
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000378:metabolism*; D001057:Apolipoproteins E / Q000378:metabolism*; D001212:Asialoglycoproteins; D002403:Cathepsins / Q000378:metabolism; D060748:Fetuins; D007668:Kidney / Q000201:enzymology; D007976:Leupeptins / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008099:Liver / Q000201:enzymology; D008247:Lysosomes / Q000201:enzymology; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012709:Serum Albumin / Q000378:metabolism; D013997:Time Factors; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D001057:Apolipoproteins E; D001212:Asialoglycoproteins; D060748:Fetuins; D007976:Leupeptins; D008075:Lipoproteins, HDL; D009842:Oligopeptides; D012709:Serum Albumin; D000509:alpha-Fetoproteins; C017029:asialofetuin; D002403:Cathepsins; C032854:leupeptin